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INTRODUCTION
Atopic dermatitis and allergen
Atopic dermatitis (AD) is a chronic, inflammatory skin disease 
with intractable pruritus. As one of the leading skin diseases in 
Westernized countries, its prevalence is increasing steadily 
world-wide,1-3 AD affects approximately 20% of pediatrics and 
1%-3% of adults,4 and 40%-60% of pediatric AD patients contin-
ue on as adult-forms later in their lives.1,5,6 Its pathogenesis is 
multifactorial with roots in a combination of genetic, environ-
mental, skin barrier, and other immunological factors. Although 
there is no single gene responsible for onset of the disease, fam-
ily history contributes in predicting prognosis of AD along with 
interplays between environmental and individual factors. Fur-
thermore, abnormalities of the skin barrier have been exten-
sively studied in the pathogenesis of AD in several studies,7-12 
and these barrier dysfunctions lead to dry and rough surfaced 
skin of AD patients. Consequently disrupted barrier leads to in-
creased rate of secondary infection and penetration of foreign 
antigens through damaged stratum corneum. 
AD can be classified into either intrinsic or extrinsic AD de-
pending on co-existence with allergic features; barrier dysfunc-
tion and increased penetration of foreign allergens of food and 
environment are closely associated with aggravation of extrinsic 
AD. In an acute stage, allergen penetrates through damaged 
skin barrier and binds with an epidermal dendritic cell (DC) ex-
pressing FcεRI which plays a role in recruiting cutaneous lym-
phocyte antigen-bearing T cell to initiate cutaneous inflamma-
tion13 and activate Th2 polarization.14,15 Also, interleukin (IL)-16 
and monocyte chemotactic protein 1 (MCP-1) produced by 
these epidermal DCs induce differentiation of monocytes into 
inflammatory dendritic epidermal cells (IDECs), which produce 
IL-1, IL-6, and tumor necrosis factor α (TNF- α). Other cytokines 
in AD pathogenesis such as IL-12 and IL-18 aid in transforma-
tion of inflammatory responses from Th2 to Th1/0 and enter 
chronic phase.16 Through above mechanisms, allergens in envi-
ronment are important in both acute phase from repetitive ex-
posure and also in chronic status of disease; hence, it is impera-
tive for extrinsic patients who have elevated serum and specific 
IgE for allergens to avoid possible exacerbating factors. And one 
of the most frequently noted allergens for AD exacerbation is a 
house dust mite (HDM).
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Pyroglyphidae Dermatophagoides farinae (Der f), Derma-
tophagoides pteronyssinus (Der p) and Euroglyphus maynei are 
the most common types of HDM. The antigenically active parti-
cles contain high enzymatic activity and act through destroying 
tight junction of epidermis, enhancing penetration of allergens 
deep into the skin.17,18 One of enzymes that HDM possesses is 
serine cysteine proteinase, and these enzymes are able to acti-
vate proteinase-activated receptors (PARs). Among many PARs, 
PAR-1, and PAR-2 are known to be most populated in respirato-
ry, gastrointestinal systems and skin.19 When PAR is activated, 
various inflammatory mediators such as IL-6 and IL-8 are se-
creted, leading to increase vascular permeability, infiltration of 
leukocytes, increased airway hypersensitivity, and other effects 
by HDM that preceded clinical symptoms of allergic diseases.20
Allergen specific immunotherapy (SIT)
Mechanisms of allergen SIT
HDM avoidance has been practiced as a part of lifestyle modi-
fication with extrinsic AD patients for quite a period. Yet as a 
more active treatment modality, SIT is receiving more attention. 
SIT was initially practiced in allergic rhinitis or asthma patients. 
Up until now, SIT is the only disease-specific treatment modali-
ty that suppresses allergic responses for a long period of time. 
SIT aims to induce allergen-specific tolerance otherwise known 
as allergen vaccination21 through acquiring immune tolerance 
with induction of allergen-specific regulatory T cells (Tregs).
The acute phase of AD is closely associated with production 
of Th2 cytokines and commonly observed Th2-biased profiles 
are suggested to be results of increased clonal expansion or dif-
ferentiation of Th2 cells or increased tendency to activation and 
apoptosis of high IFN-γ producing Th1 cells.22 These Th1 cells 
are known to be involved in apoptosis of epithelium in AD. 
Thus, induction of Treg cells during the SIT consequently in-
creases suppression of allergen-induced T-cell proliferation, 
and Th1 and Th2 cytokines.23 Thereby, we may observe clinical 
improvement of AD as a result of skin inflammation reduction 
and a diminution in epithelium apoptosis.
Tregs involved in mechanisms of SIT express IL-10, trans-
forming growth factor β (TGF-β) to elicit early phase desensiti-
zation of mast cell, basophil, and eosinophil. These allergen-
specific Tregs also suppress Th2 cells, thereby inhibiting IgE 
production, while at the same time stimulating expression of 
IgG4, a non-inflammatory immunoglobulin isotype. Also, cyto-
kines such as IL-3, IL-4, IL-5, IL-9, and IL-13 that are expressed 
from Th2 play an important role in survival, activation, and dif-
ferentiation of mast cells, basophil, and eosinophils, but SIT 
suppresses cytokine axes as well. 
Treatment methods and schedules
SIT can be divided into 2 major groups depending on the route 
of administration: sublingual (SLIT) and subcutaneous (SCIT) 
methods. While the routes may differ, both equally affect pe-
ripheral allergen-specific Tregs through similar mechanisms for 
inducing T-cell tolerance, inhibitory functions of IL-10, TGF-β, 
and reduction of mast cell and eosinophil. However, in early 
stages of treatment, expression of Treg, reduction in IgE or in-
crease in IgG4 might not be evident in SLIT compared to SCIT.24
The most important factor to consider while choosing candi-
dates for immunotherapy is finding those who are actually sen-
sitized to HDM. Therefore, majority of previously reported 
studies also enroll patients who have positive allergen sensiti-
zation to HDM. Standards for choosing candidates for SIT in 
our institution is first selecting extrinsic AD patients with serum 
total IgE above 150, and then additionally selecting only those 
who have positive reactions (over 3+) to HDM on CAP-test or 
skin prick test. We initially start the therapy in weekly regimen 
for 16-18 weeks as initial build-up phase and slowly escalates 
dosage of HDM extract, and when the maintenance dosage is 
reached, the patient visits the clinic biweekly for four times. Af-
terwards, the monthly regimen can be installed. Depending on 
clinical response, the patient can continue on with the treat-
ment for 3 to 6 years. 
There is no exact consensus for treatment period, interval 
time between treatments, and follow-up period after termina-
tion of SIT, but most literature generally agree upon 3 years as 
an ideal treatment period.25 Our institution also maintains one 
year of treatment for all those started on SIT, and continues for 
3 years unless complete remission is reached. 
Clinical efficacy of allergen SIT in AD 
Efficacy of SIT with HDM in AD 
In the past, there has been a lack of evidence of SIT in AD 
compared to that in asthma or allergic rhinitis. However, with 
increasing reports of comparable efficacy and safety of SIT in 
AD, researches are actively seeking into the field of SIT in AD as 
well. Recently published meta-analysis on 8 different random-
ized controlled trials of SIT on AD showed excellent results of 
the therapy, strengthening rationale for the treatment.26
Results from previously performed randomized controlled SIT 
are summarized in Table 1. First, in Kaufman and Roth’s study in 
1974 (United States), quasi-randomized controlled study was 
performed among total of 52 adult and pediatric AD patients.27 
A total of 26 patients completed the SCIT trial for a period of 2 
years, and significant clinical improvement was seen in 81% of 
the treatment group and 40% of the placebo group. Warner et 
al.28 conducted randomized, double-blind, placebo-controlled 
study for children with asthma (United Kingdom) and among 
20 children who possessed additional atopic features, there was 
subjective improvement of clinical eczema features as judged by 
the patients and parents in active treatment group (77.8%) com-
pared to minimal improvement in the placebo group (27.3%) af-
ter 1 year of treatment. Later, Glover and Atherton performed 
randomized, double-blind, placebo-controlled trials for HDM 
SCIT for 24 pediatric AD patients.29 The first study did not reveal 
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any statistical difference between the treatment and placebo 
groups. The second study was conducted with patients who un-
derwent active treatment in the first study and found greater 
clinical improvement, suggesting that long-term treatment for 
at least 1 year is necessary. Persistent efforts of SIT in AD contin-
ued, and a double-blind, placebo-controlled trial was conduct-
ed, for 20 adult and pediatric AD patients.30 They used W-
Atopowe zapalenie skóry (W-AZS), a Polish acronym for atopic 
dermatitis severity score to assess the extent and severity of skin 
inflammation index in AD patients concerning pruritus, sleep 
disturbances and extent and severity of skin inflammation, to 
evaluate the clinical efficacy. There was a significant decrease in 
clinical score of W-AZS index after a period of 12 months, sup-
porting growing number of evidence for efficacy. A random-
ized, double-blind, placebo-controlled trial was performed 
among a larger population of pediatric patients31 as a sublingual 
method for 18 months. Scoring atopic dermatitis (SCORAD) 
showed a dramatic decrease 9 months after the treatment and 
disease-control medication for treatment of AD was significant-
ly reduced in treatment group compared to placebo group. In 
addition, compared to baseline, visual analogue scale (VAS) 
showed tendency to decrease only in the treatment group, al-
though did not show statistical significance. Another random-
ized double-blind placebo-controlled trial by Novak et al.32 was 
conducted with 168 adult AD patients  for 18 months. Even 
though, the study did not reveal the efficacy in overall AD pa-
tients, SIT showed statistical significance of SCORAD reduction 
in subgroup of severe AD patients with SCORAD >50. Median 
reduction of total SCORAD of 18% was observed. The best out-
come was shown during September to February, due to the use 
of indoor heating and subsequent high HDM exposure. The ef-
ficacy was more pronounced with longer duration. Lastly, most 
recent randomized control trial carried out by Qin et al.33 ana-
lyzed 107 patients undergoing SLIT for 12 months. A total of 84 
patients finished the trial, compared to the placebo group 
(53.85%), treatment group (77.78%) showed improvement in 
symptoms. SIT for AD patients are practiced in Korea as well. 
But only little clinical studies have been conducted. There was 
one pilot study of SIT published by Nahm et al.34 Even though 
20 AD patients showed significant decreased in SCORAD score 
with noticeable clinical improvement after 12 months, since it 
was modified treatment methods combining SIT and hista-
mine-immunoglobulin complex treatment, it was difficult to 
see the sole and exclusive efficacy of SIT. Our institution per-
formed retrospective review on patients who underwent at least 
3 years of HDM SIT for 217 extrinsic AD patients selected 
through total IgE and CAP test or skin prick test with hypersen-
sitivity to HDM.35 Clinical improvement was judged based on 
investigator global assessment (IGA) and patients’ subjective 
assessment of symptoms. In overall, 88.4% of patients showed 
clinical improvement and among these patients, 63.9% patients 
showed complete or near-complete remission. Pruritus and 
loss of sleep was also significantly reduced with 87.2% of pa-
tients reporting improvement in pruritus, and 92.7% of patients 
with only mild or no disturbance of sleep. Hence, although the 
efficacy of SIT for extrinsic AD patients with positive reactions 
to HDM was believed to have controversial results for patients 
in the past, there is a growing trend of thought through many 
double-blind placebo-controlled trials and meta-analysis, that 
SIT is indeed an efficient and safe treatment modality for AD 
patients. While 3 to 6 years of treatment period is generally rec-
ommended in literature, there is no set evidence stating long-
term efficacy for AD patients receiving SIT for more than 3 
years. Yet retrospective review from our institution support the 
long term efficacy of SIT indicating clinical improvements are 
most significant when the treatment is continued for a mini-
mum of 3 years.
Side-effects and complications 
Both local and systemic complications can occur due to SIT. 
Table 1. Summary of characteristics and results from randomized controlled trials included in this review
Study Yearpublished Country
Study
design
Total number of
patients
(treatment, placebo)
Type of 
SIT
Type of
allergens 
Total 
duration 
(months)
Improvement Reference
Kaufman and Roth 1974 US qRCT DB PC 52 (26, 26) SCIT dander, HDM
   molds, pollen
24 (+) by physician 27
Warner et al. 1978 England RCT DB PC 20 (9, 11) SCIT HDM 12 (+) by patients 28
Glover and Atherton 1992 England RCT DB PC 24 (13, 11) SCIT HDM 8 (+) by patients 29
Silny and Czarnecka-Operacz 2006 Poland RCT DB PC 20 (10, 10) SCIT dander, HDM
   pollen
12 (+) by physician 30
Pajno et al. 2007 Italy RCT DB PC 56 (28, 28) SLIT HDM 18 (+) by physician 31
Novak et al. 2012 Germany RCT DB PC 168 (112, 56) SCIT HDM 18 (+) by physician 32
Qin et al. 2013 China RCT DB PC 107 (58, 49) SLIT HDM 12 (+) by physician 33
SIT, specific immunotherapy; qRCT, quasi-randomized controlled trial; DB PC, double-blind placebo-controlled; SCIT, subcutaneous immunotherapy; SLIT, sublingual 
immunotherapy; HDM, house-dust mite; (+), Presence.
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Based on a survey of systemic side-effects occurring SCIT in the 
past 3 years (2008-2011), there were noticeable systemic side-
effects in only 0.1% of the total 18.9 million SCIT treatment per-
formed, and there was no single case of fatal complications.36 
Majority of systemic complications occurred within 30 minutes 
of injection, and some of the delayed type response were mild 
symptoms such as a flu-like illness.37
Common local side-effects that can occur in SCIT are urticaria 
or pruritus, but majority of these reactions persist for less than 
24 hours and are rarely regarded as noticeable complications. 
Comparing with results from our institution and other RCTs 
previously performed, mild urticarial eruptions and pruritus 
occurred in only <1% of patients.38 Furthermore, in one dou-
ble-blind placebo-controlled trial, incidence of pruritus lasting 
for 1-2 days and discomfort, mild exacerbation of atopic lesions, 
urticaria, headaches or rhinitis were almost similar between the 
treatment and placebo group,26,27,31 leading to a conclusion that 
SIT is relatively a safe treatment modality. From RCTs of those 
who underwent SLIT,30,32 fatigue, headache, localized delayed 
hyper-responsiveness (>1 hour) occurred in first injection of 
the treatment, and among these side-effects, localized pruritus 
was most common. Other noted side effects were facial edema 
and gastrointestinal discomfort. Yet most of symptoms were 
mild with spontaneous resolution. There were reports of sud-
den worsening of allergic reactions or generalized pruritus in 
both placebo and control group, but the patients were all man-
ageable with a brief symptomatic treatment; no other serious 
adverse events were reported.39,40 
According to data collected from our institution, we witnessed 
urticaria, localized eruption, pruritus, exacerbation of previous 
atopic lesions, and relapse of previously known asthma in <1% 
of patients. However, the degree of symptoms was very mild, 
and the symptoms were all controllable with antihistamines. 
We believe that it is actually very difficult to accurately deter-
mine whether such reactions occur due to SIT or by exposure 
to other exogenous trigger factors. Nevertheless, from evidenc-
es collected thus far, SIT is a very safe treatment modality to in-
corporate in a clinic setting. 
Biologic effect of allergen SIT in AD
Immunologic effect and other serologic effect
There are only few reports on immunological changes ob-
served in serum or skin after SIT since most of studies thus far 
were concentrated on clinical efficacy and safety. Articles elab-
orating on changes in serum level of IgE and IgG4 are beginning 
to appear on surface, but works on variety of cytokines and che-
mokines are lacking. Considering a role of allergen as a potent 
aggravating factor in AD and complicated axes of immunology 
in AD pathomechanism, it is an important task to find efficacy 
of inducing immune tolerance through SIT and acquiring data 
that shows intricate interplay of immunologic changes before 
and after treatment. 
An explanation is needed for serum IgE level changes in re-
sponse to SIT in regards to highly activated B cells and deregu-
lation of IgE synthesis,41 but there is no clean-cut evidence. 
Studies up until now show trend of allergen-specific IgE level 
gradually decreasing after SIT.31,42-46 For total IgE, there was a 
general trend for decrease, but statistically, the results were con-
flicting with those showing significance31,46 and those that did 
not.27,29 Serum IgE begins to change relatively at a slow rate with 
no noticeable drop in its levels; moreover, since there is no evi-
dent correlation between clinical improvements after SIT treat-
ment, it is hard to explain loss or decrease of response to specif-
ic allergen only through changes in IgE.47 To many scholars, the 
role of IgE as a measurement of clinical sensitivity remains 
questionable in reality.43 Other works have stressed a significant 
decrease in Der p-specific IgG4,31,32,45,48,49 and in one pilot study, 
treatment with SIT led to decrease in markers of AD activity 
such as IL-16 and thymus and activation regulated chemokine 
(CCL17) in accordance with clinical improvement.44
 Examples of biomarker studies
Although finding a biomarker that can accurately predict 
treatment response is a necessary task, it is a challenging pro-
cess considering multifaceted and intricately woven immuno-
logic mechanisms and axes involved in allergic patients. Since 
the late 1990s, there have been many attempts to find biomark-
er candidates. In the early years, most studies concentrated on 
endothelial cell adhesion molecules,50-54 and works on chemo-
kines were published in 2000.55-58 Brief summary on history of 
biomarker studies are summarized in Table 2. Reviewing stud-
ies on biomarker up until now, there have been reports of aller-
gen-specific non-IgE antibody increasing through SIT,59 and 
several studies have shown that serum antibodies can reduce in 
vitro responses mimicking allergic reactions, such as IgE bind-
ing to allergen, IgE-facilitated antigen presentation and baso-
phil activation.60-62 In a double-blind placebo controlled study 
of grass pollen SIT, there was increase in IgG4, IgE blocking fac-
tor along with suppression of facilitated allergen binding.63 The 
authors stressed that not only IgG4, but combined assessment 
of IgG4 and IgE blocking factor can be done in order to more 
comprehensively observe functional and clinical efficacy. 
Recently, grass pollen SLIT experiment was performed in ex-
perimental exposure chamber, and the results showed comple-
ment component 1 and the receptor stabilin-1, 2 protein induc-
tion from tolerogenic DC also known as regulatory DC has cor-
relation with clinical tolerance induced by SIT.64 In addition, the 
study opened a possibility into readily selecting clinically re-
sponsive and unresponsive group through proteins that are 
easily detected through quantitative polymerase chain reaction 
in peripheral blood mononuclear cells, and explained relation-
ship of short-term efficacy with regulatory immune response. 
What exact immunologic mechanisms underlie changes in-
duced in SIT is a field of excitement that raises many questions. 
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There still remains a room to search deeper into discovering 
biomarkers and choose appropriate candidates, mechanism, 
treatment response, surrogate end points, and clinical trial for 
new drug development.65 Hence, it will not be an understate-
ment to say that the new era of AD expects a discovery of bio-
marker that can assess and standardize treatment response. If 
biologic marker can show clear-cut correlation with clinical 
symptoms, it will be an outbreak in the field of science, but con-
sidering variegated clinical pictures and associated immuno-
logical changes, the quest for a search will not be easily an-
swered upon. But through future endeavors in creating more 
high-quality standardized experiments that reflect clinical im-
provement and enable predictions of treatment end-points, we 
will be building cornerstone for biomarker discovery.
 
Further considerations and conclusion
The effectiveness of SIT has been proven through many clini-
cal studies recently published and more studies are expected in 
the future. However, there are still issues that need to be ad-
dressed before clinically applying SIT in hospital-settings. Stan-
dardized method in selecting candidate patients should be ap-
plied for institutions along with objective qualifying criteria. 
Also, effective treatment modality for those who are not solely 
sensitized to HDM (polysensitized patients) raises attention. 
There are different routes and schedules for SIT at the moment, 
and there is rush or ultra-rush protocol besides the well-known 
Table 2. Prior studies on biomarker candidates of atopic dermatitis
Candidate marker                                               Action                   Clinical results Reference
sE-selectin An adhesion molecule on endothelial cells Reflection of disease severity 50,52-54,66,67
sVCAM-1 An adhesion molecule on endothelial cells Not correlated with disease severity 51,52,54,67
sICAM-1 An adhesion molecule on endothelial cells Not correlated with disease severity 52,54
TARC/CCL17 A chemokine that attracts CCR4+ or CCR8+ cells Reflection of disease severity 55,56,58,68-72
MDC/CCL22 A chemokine that attracts CCR4+ cells Reflection of disease severity 56,57,68,69,72,73
CTACK A chemokine that attracts CCR10+ cells Reflection of disease severity 58
IL-13 An inducer of IgE production Reflection of disease severity 74
IgE Primes the IgE-mediated allergic reaction Reflection of disease severity 
No significant result
32,46,68,71,75
29,30,72,76
ECP A basic protein located in the eosinophil primary matrix Reflection of disease severity
No significant result
75,77-80
67
TEC Eosinophils control mechanisms associated with allergy Reflection of disease severity 75,79,81
sIL-2R Expressed by antigen-activated T lymphocytes Reflection of disease severity 79-81
IL-16 A chemokine that attracts CD4+ cells Reflection of disease severity 44,73,75
IL-18 An interferon-γ inducing factor Reflection of disease severity 71,82,83
BDNF A peripheral neurotrophin Reflection of disease severity 84,85
NGF A potent mediator in neuroinflammatory processes Reflection of disease severity 
Positive staining on AD skin only
No significant result
86
87
88
Substance P A neurotransmitter and a neuromodulator Reflection of disease severity
Not correlated with disease severity
86
89
CCL18 A chemokine that attracts both innate and adaptive immune cells Reflection of disease severity
Significantly decreased after Tx 
90
72
MEC/CCL28 A chemokine that attracts CCR3+, CCR10+ cells Reflection of disease severity 91,92
PF-4 A platelet chemokine Reflection of disease severity 93,94
Beta-TG A platelet chemokine Reflection of disease severity 93,94
IL-31 Associated with skin-homing CLA-positive T cells Reflection of disease severity 95
CLSP A modulator of calcium-dependent proteins Positive relation in AEAD skin 96
Der p-specific IgG4 A specific IgG molecule for Der p Reflection of disease severity 32,33,45,48,49
Underlyng bar: studies and results of SIT in AD.
sE-selectin, soluble E-selectin; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular adhesion molecule-1; TARC, thymus and activation-
regulated chemokine; CCL, C-C motif ligand; CCR, chemokine receptor; MDC, macrophage-derived chemokine; CTACK, cutaneous T cell-attracting chemokine; IL-13, 
interleukin-13; ECP, eosinophil cationic protein; TEC, total eosinophil count; sIL-2R, soluble IL-2 receptor; BNDF, brain-derived neurotrophic factor; NGF, nerve growth 
factor; Tx, treatment; MEC, mucosa-associated epithelial chemokine; PF-4, platelet factor 4; beta-TG, beta-thromboglobulin; CLA, cutaneous lymphocyte antigen; 
CLSP, calmodulin-like skin protein; AEAD, acute exacerbated.
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conventional protocol. In the future, a development for a safe 
protocol which enables faster immune reaction is promising. If 
we can perform further studies to see whether early interven-
tion allows for blocking progression into allergic march, we will 
be opening many doors into prevention and treatment of vari-
ous allergic diseases. Endeavors in optimizing preparations 
used and improving treatment response with more refined al-
lergoids, potent adjuvants, or recombinant vaccine are also 
suggested. Lastly, more work should be done in an attempt to 
discover biomarkers for SIT that will allow clinicians to predict 
the outcomes or to judge appropriate treatment duration for 
the patients. Uncovering a new biomarker shall advance the 
upcoming development and applications of SIT.
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